Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients

Siddhesh A Kamat, Steve Offord, John Docherty, Jay Lin, Anna Eramo, Ross A Baker, Benjamin Gutierrez, Craig Karson

Article Type

Original Research

Published

The results from this large cohort study provided naturalistic real-world evidence of the utility of LAIs in patients with schizophrenia and suggest that these agents may help to reduce the risk of relapse across all age groups, especially among younger patients.

Read more

Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations

Jungjin Kim, Eric MacMaster, Thomas L Schwartz

Article Type

Case Report

Published

Tardive dyskinesia (TD) can be a disfiguring side-effect of antipsychotic medications. In this article the authors review the risk of TD, the potential etiologic mechanisms and present some interesting cases of patients taking atypical antipsychotics who developed TD.

Read more

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries

Murat Altin, Ahmed A El-Shafei, Maria Yu, Durisala Desaiah, Tamas Treuer, Nikolay Zavadenko, Hong Yun Gao

Article Type

Original Research

Published

This prospective, observational, non-interventional study conducted in six non-Western countries concludes that after 12 months of treatment, clinical and functional outcomes were improved in children and adolescents with attention deficit hyperactivity disorder (ADHD) who initiated and remained on their prescribed pharmacological monotherapy.

Read more

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary

Susan G Ball, Durisala Desaiah, Qi Zhang, Michael E Thase, David G S Perahia

Article Type

Review

Published

Major depressive disorder (MDD) is a significant public health concern and challenges health care providers to intervene with appropriate treatment. This review provides evidence that duloxetine 60 mg QD is effective for the treatment of adult patients with MDD in the short- and long-term phases of treatment. Duloxetine 60 mg QD also represents a viable choice of treatment for those patients with painful physical symptoms associated with MDD.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.